What is it about?
Tocotrienol is a strong anti-oxidative agent and has an anti-inflammatory effect. Considering that atrial fibrillation is a known complication of heart surgery with an incidence of almost 30% in our institution with an increased risk of stroke, morbidity and mortality, and a prolonged hospital stay; and taking cognizant that the pathway for this complication is mediated by oxidative stress and inflammatory pathway, we hypothesized that tocotrienol might play a role in reducing atrial fibrillation after coronary artery bypass grafting surgery.
Featured Image
Why is it important?
If our hypothesis is correct, then the incidence of atrial fibrillation after bypass surgery can be reduced. And this would also reduce the morbidity and mortality associated with this complication post-surgery. Furthermore it would reduce the time spent by patients in ICU, HDU and the overall hospital stay which means reducing the costs and an increase in economic productivity.
Perspectives
This project will prove that Cardiothoracic Surgeons not only care about treating coronary artery bypass patients but also think about ways in reducing the post-operative complications and improve the quality of life of patients. The three co-researchers at the National Heart Institute are Senior Cardiothoracic Surgery Consultants and have vast experience in cardiothoracic surgery. They have been my long-term collaborators in many of my research projects.
Dato' Dr Ahmad Farouk Musa
Monash University
Read the Original
This page is a summary of: A study protocol for a randomized controlled trial on the prevention of atrial fibrillation after coronary artery bypass grafting surgery using Tocotrienol, an isomer of Vitamin E derived from palm oil, F1000Research, February 2018, Faculty of 1000, Ltd.,
DOI: 10.12688/f1000research.12912.1.
You can read the full text:
Resources
Contributors
The following have contributed to this page
